340B Reform: Who Profits From Drug Discounts Now?
The 340B drug discount program is well-intentioned, but it’s also been widely exploited. It was designed to let safety-net hospitals and clinics buy outpatient drugs at steep discounts, then use the resulting revenue to fund safety-net programs. Makes perfect sense.
But as the number of covered entities has grown, so has the amount of net revenue hospitals can keep—and there’s still minimal transparency into what they do with that money. Does it fund charity care, or does it pay for a new outpatient oncology infusion center?
Like most issues I write about, following the money usually explains what’s going on. This program has grown by an average of 22% annually **over the past 15 years. The estimated value is $80 billion.
In this article, I’ll break down 340B simply, walk through the best available data, and then lay out what reform could look like.
The Deets: 340B Program
The 340B Drug Pricing Program requires drug manufacturers to sell outpatient drugs at steep discounts to certain healthcare organizations (“covered entities”) that serve low-income and uninsured populations.
The program is conceptually simple: Give safety-net hospitals discounts on expensive drugs so they can use the savings to expand care for underserved patients.
In reality, though, it’s complicated.
The drug supply chain was already messy, and the 340B program made it even messier. Before I break it all down, here are the key players you need to know:
Covered Entities: Safety-net hospitals, children’s hospitals, critical access hospitals, family planning clinics, and FQHCs.
Pharmaceutical Companies: Drug manufacturers that provide discounts—but are actively pushing for 340B reform.
PBMs and Contract Pharmacies: The middlemen profiting from 340B. PBMs lower reimbursements to hospitals, while contract pharmacies (CVS, Walgreens, etc.) share in the revenue without passing discounts to patients. More on this below.
Patients: The intended beneficiaries but often left out of the financial equation.
How Are 340B Discounts Determined?
Unlike insurance reimbursement rates or value-based pricing models, 340B pricing is pretty basic… there’s not much science to it: the discount is equal to the average manufacturer price (AMP) minus the unit rebate amount:
Average Manufacturer Price (AMP): The average price wholesalers and pharmacies pay manufacturers for a drug (this is not to be confused with the list price, which is often inflated).
Unit Rebate Amount (URA): The mandatory discount manufacturers must provide, typically:
~23% for most brand-name prescription drugs
~17% for pediatric brand-name drugs
~13% for generics and over-the-counter drugs
So if the average manufacturer price for my brand name Huddlelizumab is $10,000 per month, then covered entities would pay $7,700 for just one month of the drug.
Follow the Money: How 340B Creates Profits for Hospitals and Pharmacies
The thought behind the program is that if you give these entities large discounts on drugs, they can use the revenue to invest more into their underserved patient population (e.g., uncompensated care). Notably, there are no guidelines dictating how covered entities use the revenue reaped from the program.
Let’s walk through a fake 340B revenue example using HuddleHospital and Huddlelizumab, made by HuddleTherapeutics:
HuddleTherapeutics sets the price of Huddlelizumab at $10,000 per month.
HuddleHospital participates in 340B because 15% of its patient population is on Medicaid.
HuddleHospital purchases a one-year supply for 100 privately insured patients at the 340B discounted price of $9.24 million instead of $12 million (a gross-to-net difference of $2.76 million).
Those 100 privately insured patients receive Huddlelizumab, and their insurance companies pay HuddleHospital the full $10,000 per dose (or close to it, depending on negotiated rates).
HuddleHospital profits $2.76 million from the difference between the discounted price and insurer reimbursement.
What Happens If There’s No In-House Pharmacy?
Not all hospitals dispense drugs directly. Many contract with retail pharmacies like CVS or Walgreens or PBMs. In this scenario:
HuddleHospital purchases a one-year supply for 100 privately insured patients at the 340B discounted price of $9.24 million instead of $12 million.
HuddleHospital pays CVS Pharmacy a distribution fee to dispense Huddleizumab.
CVS Pharmacy receives full reimbursement from insurers (the same way hospitals do).
They keep a portion of the revenue and pass the rest to the hospital.
The result? More middlemen, more profits—but patients still don’t see direct savings.
Anyway, now, what will HuddleHospital do with nearly $3 million? They reinvest the money into charity care, free medication programs, or expanding patient services. But then an investigative report finds HuddleHospital has actually kept the profit, and used it to expand their services into wealthier areas.
What now?
340B Program Growth and Outcomes
Growth
When I last wrote about 340B, the program had hit $66 billion in discounted purchases in 2023. Now the number is even larger. According to HRSA data (which is likely an underestimate), discounted 340B purchases reached about $81 billion in 2024, then crossed $100 billion in 2025. That is a roughly 23% jump in one year.
Zoom out and the growth is even more striking….
This article is fully available for HuddleLite and Huddle+ members!
